Bayer : Good FY 2022 driven by Crop Science – 2023 Outlook disappoints
>Crop Science drives FY 2022 – Pharma and Consumer Health below expectations - At a group level, Bayer’s Q4 2022 figures came in above expectations. Sales were at € 12bn (+7.9%), roughly in line with our (€ 11.8bn) and consensus estimates (€ 12.1bn), while EBITDA of € 2,462m (+2.8%) came in 8.9% above our estimates (€ 2,260m) and 2% above the consensus (€ 2,413m). The strong profitability was clearly driven by the Crop Science division, which increased its Q4 adj. EBI...Bayer is a life sciences group based in Germany. Co.'s operations are organized along three divisions: Pharmaceuticals (engaged in prescription pharmaceuticals for cardiology and women's healthcare); Consumer Health (engaged in non-prescription products in dermatology, dietary supplement, analgesic, gastrointestinal, allergy, cold and flu, foot care, sun protection and cardiovascular risk prevention categories); and CropScience (engaged in the development of seeds and plant traits; crop protection; and for gardens, the green industry and non-agricultural pest control). Co. also maintains an Animal Health business unit engaged in the development of products for farm and companion animals.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.